Status | Study |
Completed |
Study Name: Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis Condition: Facial Angiofibroma Date: 2017-04-26 Interventions: Drug: Rapamycin |
Recruiting |
Study Name: Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies Condition: Proteus Syndrome PIK3CA-Related Overgrowth Spectrum (PROS) Date: 2017-03-17 Interventions: Drug: ARQ 092 Subjects will receive ARQ 092 orally at the dose level and administration schedule specifi |
Recruiting |
Study Name: Familial Investigations of Childhood Cancer Predisposition Condition: Acute Leukemia Adenomatous Polyposis Adrenocortical Carcin Date: 2017-02-08 |
Recruiting |
Study Name: RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (PTEN) Condition: PTEN Gene Mutation PTEN Hamartoma Tumor Syndrome Date: 2016-12-02 Interventions: Drug: RAD001 |
Recruiting |
Study Name: Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France Condition: Tuberous Sclerosis Complex Date: 2016-08-30 |
Not yet recruiting |
Study Name: Topical Everolimus in Patients With Tuberous Sclerosis Complex Condition: Facial Angiofibromas Date: 2016-08-04 Interventions: Drug: Everolimus Everolimus to |
Recruiting |
Study Name: Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex Condition: Tuberous Sclerosis Complex Date: 2016-02-10 Interventions: Behavioral: JASPER JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment ap |
Not yet recruiting |
Study Name: Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex Condition: Tuberous Sclerosis Angiofibroma Hypomelanotic Macule Date: 2015-12-16 Interventions: Drug: NPC-12G gel NPC-12G gel is administered topically twice a day for 52 weeks or longer |
Completed |
Study Name: Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) Condition: Tuberous Sclerosis Angiofibroma Hypomelanotic Macule Date: 2015-12-15 Interventions: Drug: NPC-12G gel NPC-12G gel |
Recruiting |
Study Name: Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas Condition: Basal Cell Carcinoma Date: 2015-12-14 Interventions: Drug: Vismodegib Vismodegib 150 mgs po qd for 3 months |